Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AC Interleukin inhibitors
L04AC17 Tildrakizumab
D10400 Tildrakizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Interleukin Blockers
Tildrakizumab
D10400 Tildrakizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D10400 Tildrakizumab (USAN); Tildrakizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Immunological agent
DG02019 Interleukin inhibitor
D10400 Tildrakizumab
Drug classes [BR:br08332]
Immunological agent
DG02019 Interleukin inhibitor
D10400 Tildrakizumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Interleukins
IL23A
D10400 Tildrakizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10400
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10400
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10400
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10400
